Spero Therapeutics Inc KOL Breakfast Symposium: A Focus on the Spero Pipeline Transcript
Great. Thank you, everyone, for coming to our event. We'll first dive into our Phase III product candidate, SPR994, now called tebipenem HBr, including a presentation from Dr. Yoav Golan on the unmet need in the complicated urinary tract infection area. We'll then move to SPR720. We announced the Phase I data on the compound yesterday, and our plan is to move forward into a Phase II in NTM patients. We'll be taking questions after each presentation, and I'll now pass it over to Ankit Mahadevia, President and CEO of Spero Therapeutics.
Thank you, Sharon, and thanks for all of you for coming in this morning and for all of you that are listening on the web. We are excited to present our progress both on 994 as well as on SPR720.
So as always, I'd like to start our discussion about our pipeline with a discussion about patients. And this is a patient named Tim, who was kind enough to share his story with the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |